The Health Resources and Services Administration released updated cervical cancer screening guidelines that include a new option for women to self-collect samples for screening.
The Alliance for Clinical Trials in Oncology initiated a randomized phase III clinical trial called RECIPROCAL to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.
Researchers at WashU Medicine and their collaborators created an immune cell atlas of the bone marrow of patients with multiple myeloma, which researchers hope could improve prognosis and guide development of new immunotherapies.
A research team at Oregon Health & Science University discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
A study from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, reveals how two genetic mutations, IDH2 and SRSF2, cooperate to erroneously splice RNA messages and disrupt the cell’s identity.
A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, found a mechanism that allows breast cancer to send metastases to the brain. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.
Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery.
FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer.
FDA granted breakthrough therapy designation to Enhertu (trastuzumab deruxtecan) for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.
